8-chloroguanosine | 2104-68-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 8-chloroguanosine
• 英文别名: 8-Chloroguanosine；2-amino-8-chloro-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
• CAS: 2104-68-9
• 化学式: C₁₀H₁₂ClN₅O₅
• 分子量: 317.689
• InChiKey: KZEYUNCYYKKCIX-UMMCILCDSA-N

物化性质

• 密度：
  2.35±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  155
• 氢给体数：
  5
• 氢受体数：
  7

制备方法与用途

8-氯鸟苷是一种嘌呤核苷类似物，这类化合物具有广泛抗肿瘤活性，尤其针对惰性淋巴系统恶性肿瘤。其抗癌机制主要通过抑制DNA合成和诱导细胞凋亡来实现。

反应信息

• 作为产物：
  描述：

  鸟苷 在 盐酸 、 间氯过氧苯甲酸 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 2.0h， 以39.6%的产率得到8-chloroguanosine
  参考文献：
  名称：

  New procedure for the chlorination of pyrimidine and purine nucleosides

  摘要：

  DOI：

  10.1021/jo00326a053

文献信息

• [EN] BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY<br/>[FR] CONJUGUÉS BIOACTIFS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
  申请人：UNIV MASSACHUSETTS

  公开号：WO2017030973A1

  公开（公告）日：2017-02-23

  Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.

  本文提供的自递送寡核苷酸具有高效的RISC进入、最小的免疫反应和非靶效应、无需配方的高效细胞摄取，以及高效和特异的组织分布。
• BRANCHED LIPID CONJUGATES OF siRNA FOR SPECIFIC TISSUE DELIVERY
  申请人：UNIVERSITY OF MASSACHUSETTS

  公开号：US20210108200A1

  公开（公告）日：2021-04-15

  This disclosure relates to an siRNA-lipid conjugate of formula Y-L-(H) n . Y is an siRNA molecule, L is a linker covalently bonded to Y and H, each H is independently a hydrophobic chain comprising 5 to 50 carbon atoms, n is 1, 2, or 3, and linker L is bonded to the 3′ end of the sense strand of the siRNA.

  这项披露涉及到一个公式为Y-L-(H)n的siRNA-脂质共轭物。其中，Y是一个siRNA分子，L是与Y和H共价结合的连接物，每个H都是独立的由5到50个碳原子组成的疏水链，n为1、2或3，连接物L与siRNA的sense链的3'端结合。
• [EN] ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED METHODS<br/>[FR] OLIGONUCLÉOTIDES ANTI-ADAM33 ET PROCÉDÉS ASSOCIÉS
  申请人：UNIV MASSACHUSETTS

  公开号：WO2018226788A1

  公开（公告）日：2018-12-13

  The present disclosure provides antisense compounds, methods, and compositions for silencing ADAM33 mRNA. The present disclosure provides antisense compounds, methods, and compositions for the treatment, prevention, or amelioration of diseases, disorders, and conditions associated with ADAM33 in a subject in need thereof. Also contemplated are antisense compounds and methods for the preparation of a medicament for the treatment, prevention, or amelioration of a disease, disorder, or condition associated with ADAM33.

  本公开提供反义物质，方法和组合物，用于沉默ADAM33 mRNA。本公开提供反义物质，方法和组合物，用于治疗、预防或改善与ADAM33有关的疾病、障碍和病况的患者。还考虑了反义物质和方法，用于制备用于治疗、预防或改善与ADAM33有关的疾病、障碍或病况的药物。
• Methods and compositions for enhancing the efficacy and specificity of RNAi
  申请人：University of Massachusetts

  公开号：EP2314692A2

  公开（公告）日：2011-04-27

  A method of enhancing the efficacy of an siRNA duplex, or promoting entry of an antisense strand of an siRNA duplex into a RISC complex, the siRNA duplex comprising the antisense strand and a complementary strand, the strands each having 5' and 3' ends, the method comprising enhancing the asymmetry of the siRNA duplex by lessening the base pair strength between the 5' end of the antisense strand (AS 5') and the 3' end of the sense strand (S 3') relative to the base pair strength between the 3' end of the antisense strand (AS 3') and the 5' end of the sense strand (S 5'), such that efficacy of the siRNA duplex is enhanced, or entry of the antisense strand into the RISC complex is promoted.

  一种提高 siRNA 双链的效力或促进 siRNA 双链的反义链进入 RISC 复合物的方法，该 siRNA 双链包括反义链和互补链，两条链分别具有 5' 端和 3' 端、该方法包括通过降低反义链 5'端（AS 5'）和有义链 3'端（S 3'）之间的碱基对强度（相对于反义链 3'端（AS 3'）和有义链 5'端（S 5'）之间的碱基对强度）来增强 siRNA 双链的不对称性，从而增强 siRNA 双链的功效，或促进反义链进入 RISC 复合物。
• RNA interference for the treatment of gain-of-function disorders
  申请人：University of Massachusetts

  公开号：EP2821085A2

  公开（公告）日：2015-01-07

  The present invention relates to the discovery of an effective treatment for a variety of gain-of-function diseases, in particular, Huntington's disease (HD). The present invention utilizes RNA Interference technology (RNAi) against polymorphic regions in the genes encoding various gain-of-function mutant proteins resulting in an effective treatment for the gain-of-function disease.

  本发明涉及发现一种有效治疗各种功能增益性疾病，特别是亨廷顿氏病（HD）的方法。本发明利用 RNA 干扰技术（RNAi）对编码各种功能增益突变蛋白的基因中的多态区进行干扰，从而有效治疗功能增益疾病。